Immuron Ltd Secures Exclusive US Distribution Rights for PROIBS in $4.16B Market [VIDEO]
Immuron's exclusive Immuron PROIBS US Distribution Deal with Calmino group AB targets a slice of the $4.16 billion US gut health market, backed by a decade of Swedish pharmacy sales and 94% user satisfaction from a 1,003-person study.
Key Takeaways
- Immuron has signed an exclusive US distribution agreement for PROIBS® with Swedish life science company Calmino group AB, announced 4 September 2026.
- PROIBS® is a European-certified medical device with over a decade of commercial history on the Swedish pharmacy market, reducing the product risk typically associated with new market entrants.
- A usability study of 1,003 users reported 94% found the product helpful, 91% experienced improvement in daily life, and 98% would recommend it — providing documented demand evidence ahead of the US rollout.
- Immuron's US revenue from Travelan® grew 13% in USD terms to USD$1.2 million in FY26, establishing the commercial infrastructure on which the PROIBS® US strategy is being built.
- The company's cash balance improved by $6.2 million to $9.0 million in FY26, with gross profit margins at 64.5%, giving Immuron runway to activate the US distribution agreement without near-term dilution pressure.
![Firstwave Cloud Technology Ltd Files AI Network Fault Diagnosis Patent [VIDEO]](https://media.stockwirex.com/Data-Center-Display.jpg)
![Hubify Ltd Frames 89% EBITDA Lift Around AI First Managed Intelligence Pivot [VIDEO]](https://media.stockwirex.com/data_center_hfy.jpg)
![Aland Equity Group Locks in Rights to Sell 56 Lots Targeting $75K Net Per Lot [VIDEO]](https://media.stockwirex.com/land-for-sale-sign.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X Pty Ltd (CAR No. 001 322 642) is a Corporate Authorised Representative of ShareX Pty Ltd (AFSL No. 519872), regulated by the Australian Securities and Investments Commission (ASIC). StockWire X is authorised to provide general financial product advice in relation to basic deposit products, securities, and managed investment schemes.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer